HomeCompareRPHM vs SPHD

RPHM vs SPHD: Dividend Comparison 2026

RPHM yields 10.99% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPHM wins by $14.8K in total portfolio value
10 years
RPHM
RPHM
● Live price
10.99%
Share price
$18.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.3K
Annual income
$2,186.89
Full RPHM calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — RPHM vs SPHD

📍 RPHM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPHMSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPHM + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPHM pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPHM
Annual income on $10K today (after 15% tax)
$934.07/yr
After 10yr DRIP, annual income (after tax)
$1,858.86/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, RPHM beats the other by $1,373.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPHM + SPHD for your $10,000?

RPHM: 50%SPHD: 50%
100% SPHD50/50100% RPHM
Portfolio after 10yr
$33.9K
Annual income
$1,379.10/yr
Blended yield
4.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RPHM right now

RPHM
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Altman Z
-0.1
Piotroski
3/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPHM buys
0
SPHD buys
0
No recent congressional trades found for RPHM or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPHMSPHD
Forward yield10.99%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$41.3K$26.5K
Annual income after 10y$2,186.89$571.32
Total dividends collected$16.4K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RPHM vs SPHD ($10,000, DRIP)

YearRPHM PortfolioRPHM Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$11,799$1,098.90$11,133$432.85+$666.00RPHM
2$13,837$1,211.76$12,363$450.36+$1.5KRPHM
3$16,133$1,328.07$13,695$467.39+$2.4KRPHM
4$18,710$1,447.20$15,138$483.90+$3.6KRPHM
5$21,588$1,568.52$16,697$499.88+$4.9KRPHM
6$24,791$1,691.42$18,382$515.31+$6.4KRPHM
7$28,341$1,815.27$20,198$530.17+$8.1KRPHM
8$32,264$1,939.50$22,157$544.46+$10.1KRPHM
9$36,587$2,063.54$24,266$558.18+$12.3KRPHM
10$41,334$2,186.89$26,536$571.32+$14.8KRPHM

RPHM vs SPHD: Complete Analysis 2026

RPHMStock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Full RPHM Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this RPHM vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPHM vs SCHDRPHM vs JEPIRPHM vs ORPHM vs KORPHM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.